Aytu BioPharma will report its third quarter fiscal 2023 financial results on May 11, 2023

ENGLEWOOD / ACCESSWIRE / 5 May 2023 Aytu BioPharma, Inc., (the Company, or “Aytu”), a commercial-stage pharmaceutical and consumer-health company that provides pediatric-focused prescription medications and cost-effective health solutions for consumers, will announce financial results of its third quarter fiscal 2023, ending March 31, 2023, following the close of markets on Thursday, May 11 2023. The Company has scheduled an afternoon conference call for Thursday, May 11th, 2023 at 4:30pm ET.

Conf Call Information

Date and time: Thursday, May 11, 2023, at 4:30 pm ET

Call-in InformationInterested parties may access the conference call using the participant code 937039 by dialing 888-506-0062 or 973-528-0011.

Webcast Information You can access the webcast live and archived by clicking on this link.

https://www.webcaster4.com/Webcast/Page/2142/48110 and on Aytu BioPharma’s website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.

Replay: You can access a teleconference replay until May 25, 2023 by dialing (877) 481-4010 or (919 882-2331, with replay access code 48110.

Aytu BioPharma, Inc.
Aytu BioPharma has a diverse portfolio of consumer and prescription health products. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu’s Consumer Health segment sells a wide range of over the counter medicines, personal products, and dietary supplement products that treat a wide range of conditions such as diabetes, allergy and hair regrowth. For more information, please visit aytubio.com.

Contacts for investors:
Mark Oki, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]

Robert Blum and Roger Weiss
Lytham Partners
[email protected]

SOURCE: Aytu BioPharma, Inc.

View source version at accesswire.com

Previous post Which Boston Celtics alumni have won the most playoff games?
Next post 31 bedroom lighting designs to make your space look amazing